| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/20-1/50 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | DDAH; DDAH II; DDAH2; DDAHII; Dimethylargininase 2; G6a;;DDAH2 |
| WB Predicted band size | 30 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human DDAH2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于DDAH2抗体的3篇参考文献示例(内容基于已有研究主题模拟，非真实文献)：
---
1. **标题**: *"Dimethylarginine dimethylaminohydrolase 2 (DDAH2) modulates nitric oxide synthesis in endothelial cells through post-translational regulation"*
**作者**: Smith JL, et al.
**摘要**: 研究利用DDAH2特异性抗体敲低其表达，发现DDAH2通过降解ADMA(非对称二甲基精氨酸)调控一氧化氮合酶(NOS)活性，进而影响内皮细胞功能，提示其在血管稳态中的关键作用。
2. **标题**: *"DDAH2 overexpression attenuates diabetic nephropathy via ADMA-NO pathway in a rat model"*
**作者**: Chen H, et al.
**摘要**: 通过免疫组化(使用DDAH2抗体)发现糖尿病肾病大鼠模型中DDAH2表达下调，过表达DDAH2可降低ADMA水平、改善肾脏氧化应激，表明其可能成为治疗靶点。
3. **标题**: *"Role of DDAH2 in tumor angiogenesis: Antibody-based inhibition suppresses glioma progression"*
**作者**: Wang T, et al.
**摘要**: 研究采用DDAH2中和抗体抑制胶质瘤细胞功能，发现其通过减少肿瘤微环境中的一氧化氮生成，显著抑制血管生成及肿瘤生长，为癌症治疗提供新思路。
---
*注：以上为模拟文献，建议通过PubMed、Google Scholar等平台以“DDAH2 antibody”或“DDAH2 function”为关键词检索真实文献。*
DDAH2 (dimethylarginine dimethylaminohydrolase 2) is an enzyme critical in regulating nitric oxide (NO) synthesis by metabolizing asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase (NOS). As a key component of the NO pathway, DDAH2 influences vascular tone, endothelial function, and immune responses. Unlike its isoform DDAH1. which is widely expressed, DDAH2 shows more restricted expression, primarily in tissues like the liver, kidneys, and immune cells.
Antibodies targeting DDAH2 are essential tools for studying its expression, localization, and functional roles in physiological and pathological contexts. Research using DDAH2 antibodies has linked altered DDAH2 activity to cardiovascular diseases (e.g., hypertension, atherosclerosis), renal dysfunction, and inflammatory conditions, where dysregulated NO signaling contributes to pathogenesis. These antibodies enable detection via techniques like Western blotting, immunohistochemistry, and ELISA, aiding in quantifying protein levels or assessing post-translational modifications.
Recent studies also explore DDAH2's role in cancer and metabolic disorders, highlighting its broader therapeutic relevance. However, challenges remain in ensuring antibody specificity due to structural similarities between DDAH isoforms. Validated DDAH2 antibodies are crucial for clarifying its tissue-specific functions and developing targeted therapies to modulate NO pathways in disease.
×
